Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TBTC Study 29: Evaluation of a Rifapentine-Containing Regimen for Intensive Phase Treatment of Pulmonary Tuberculosis

Next Previous
Search
Trial Profile

TBTC Study 29: Evaluation of a Rifapentine-Containing Regimen for Intensive Phase Treatment of Pulmonary Tuberculosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rifapentine (Primary) ; Rifampicin
  • Indications Pulmonary tuberculosis
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 12 Jul 2021 Results of a longitudinal model-based biomarker analysis of exposure response of data pooled from 2 clinical trials (Study 29 and study 29X) published in the Antimicrobial Agents and Chemotherapy
    • 17 Mar 2021 Results (n= 2744) of pooled analysis from 3 studies (NCT00864383, NCT01498419 & NCT00694629) evaluating short term time to positivity (TTP) biomarker in liquid culture as a predictor of individual TSCC and trial level HR, presented at the 122nd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 07 May 2014 Trial status changed to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top